Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia

International Journal of Gynecological Pathology

Volumn 28, Issue 5, 2009, Pages 471-476

  Quddus, M Ruhul ^a   Ologun, Babatunde A ^a   Sung, C James ^a   Steinhoff, Margaret M ^a   Lawrence, W Dwayne ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Atypical endometrial hyperplasia; Endometrial surface epithelial change; PTEN

Indexed keywords

EOSIN; HEMATOXYLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER SURGERY; CELL STRUCTURE; CELL SURFACE; CLINICAL ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PAPANICOLAOU TEST; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PRECANCEROUS CONDITIONS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 69749104721     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181a06f96     Document Type: Article

References (17)

1. Jacques SM, Qureshi F, Lawrence WD. Surface epithelial changes in endometrial adenocarcinomas: diagnostic pitfalls in curettage specimens. Int J Gynecol Pathol 1995;14:191-197
2. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-931
3. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55:326-331
4. Latta E, Chapman WB. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 2002;14:59-65. (Pubitemid 34177909)
5. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
6. An H-J, Lee Y-H, Cho N-H, et al. Alteration of PTEN expression in endometrial carcinoma is associated with downregulation of cyclin- dependent kinase inhibitor, p27. Histopathology 2002;41:437-445
7. Tamura M, Gu J, Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130cas. Cancer Res 1999;59:4342-4349 (Pubitemid 29048881)
8. Lesli NR, Downes CP. PTEN: the down side of PI3 kinase signaling. Cellular Signaling 2002;14:285-295
9. Vasquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3 kinase signaling. Biochemica et Biophisica Acta 2000;1470:21-35.
10. Zhu X, Kwon CH, Schlosshauer PW, et al. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 2001;61:4569-4575
11. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006;37:1465-1472 (Pubitemid 44584324)
12. Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008;21:131-139 (Pubitemid 351172164)
13. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immuno-cytochemical study. Int J Gynecol Cancer 2007;17:697-704. (Pubitemid 46744009)
14. Maneschi M, Maneschi F, Geraci P. Surgical pathological staging of endometrial carcinoma and results of treatment. Eur J Gynecol Oncol 1992;13:30-35.
15. Bonatz G, Luttes J, Hamann S, et al. Immunohistochemical assessment of p170 provides prognostic information in endometrial carcinoma. Histopathology 1999;34:43-50. (Pubitemid 29049075)
16. Lacey JV Jr, Mutter GL, Ronnett BM, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68:6014-6020
17. Quddus MR, Sung CJ, Zheng W, et al. P53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999;35:44-49. (Pubitemid 29325296)